Jennison Associates LLC Has $558,000 Stake in Amedisys Inc (AMED)
Jennison Associates LLC reduced its position in Amedisys Inc (NASDAQ:AMED) by 60.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,890 shares of the health services provider’s stock after selling 13,350 shares during the period. Jennison Associates LLC’s holdings in Amedisys were worth $558,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new position in shares of Amedisys during the first quarter worth $123,000. State of Alaska Department of Revenue boosted its position in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares in the last quarter. CIBC Asset Management Inc bought a new position in shares of Amedisys during the second quarter worth $230,000. SG Americas Securities LLC boosted its position in shares of Amedisys by 48.7% in the second quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after buying an additional 1,226 shares in the last quarter. Finally, Redmile Group LLC bought a new position in shares of Amedisys during the first quarter worth $247,000. 96.80% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amedisys Inc (NASDAQ:AMED) opened at 49.76 on Thursday. The stock’s 50 day moving average price is $52.57 and its 200 day moving average price is $54.43. Amedisys Inc has a one year low of $34.58 and a one year high of $65.91. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 42.53 and a beta of 0.89.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.12. The firm had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 EPS. Analysts expect that Amedisys Inc will post $2.21 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/jennison-associates-llc-has-558000-stake-in-amedisys-inc-amed/1533301.html.
Several equities analysts have weighed in on the company. Mizuho raised Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 target price on the stock in a research note on Wednesday, May 3rd. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 12th. Stephens lifted their target price on Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research note on Thursday, May 4th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 target price on shares of Amedisys in a research note on Monday, June 5th. Finally, Benchmark Co. reaffirmed a “hold” rating and set a $57.00 target price (up previously from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Seven analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $56.33.
In other Amedisys news, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the sale, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce D. Perkins acquired 2,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were bought at an average cost of $46.60 per share, with a total value of $93,200.00. Following the completion of the acquisition, the director now directly owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Insiders own 2.80% of the company’s stock.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.